基于[68Ga]Ga-FAPI-04 PET、[18F]FDG PET与增强MRI预测局部晚期直肠癌病理完全缓解:与病理学的逐病灶比较
研究纳入20例局部晚期直肠癌患者,在新辅助短程放疗联合免疫化疗前后行[68Ga]Ga-FAPI-04 PET/MRI、[18F]FDG PET/CT及增强MRI,逐病灶与病理对照。术后9例(45.0%)达pCR;定量指标[68Ga]Ga-FAPI-04的SULpeak变化百分比曲线下面积最大(0.929),截断值63.92%。作者认为[68Ga]Ga-FAPI-04 PET/MRI是有前景的预测方法。
要点
- 20例局部晚期直肠癌患者接受新辅助短程放疗联合2周期卡培他滨、奥沙利铂及卡瑞利珠单抗,术后9例(45.0%)达pCR。
- 视觉评估中[68Ga]Ga-FAPI-04 PET/MRI与[18F]FDG PET/CT对pCR的预测能力均有限,增强MRI预测pCR的敏感度为55.56%。
- 定量评估中[68Ga]Ga-FAPI-04的SULpeak变化百分比曲线下面积最大(0.929),截断值63.92%时敏感度77.78%、特异度100.0%。
核心结论
- [68Ga]Ga-FAPI-04 PET/MRI是预测短程放疗联合免疫化疗后pCR的有前景的影像方法,SULpeak下降超过63.92%可能为筛选可免除手术的患者提供有价值指导。
研究设计与样本
- 研究纳入2023年2月至2023年7月组织学确诊的初治局部晚期直肠癌患者,术前接受新辅助短程放疗后2周期卡培他滨和奥沙利铂联合卡瑞利珠单抗。
- 每例患者在治疗开始前和手术前均行[68Ga]Ga-FAPI-04 PET/MRI、[18F]FDG PET/CT和增强MRI,收集PET与MRI特征及病灶大小和数量。
- 各参数的敏感度、特异度和诊断截断值通过受试者工作特征曲线分析得出。
主要发现
- 20例符合条件患者(男13例、女7例;平均年龄60.2岁)完成整个试验,均为错配修复功能完整或微卫星稳定型局部晚期直肠癌。
- 术后9例(45.0%)达到pCR。
- 视觉评估中[68Ga]Ga-FAPI-04 PET/MRI和[18F]FDG PET/CT对pCR的预测能力均有限。
- 增强MRI预测pCR的敏感度较低,为55.56%。
- 定量评估中[68Ga]Ga-FAPI-04的SULpeak变化百分比曲线下面积最大(0.929),敏感度77.78%、特异度100.0%、截断值63.92%。
关键数值与推荐
- [68Ga]Ga-FAPI-04的SULpeak变化百分比截断值63.92%时,预测pCR的敏感度77.78%、特异度100.0%、曲线下面积0.929。
- 增强MRI预测pCR的敏感度为55.56%。
- 术后pCR率为45.0%(9/20例)。
临床怎么用
- 作者认为[68Ga]Ga-FAPI-04 PET/MRI是预测短程放疗联合免疫化疗后pCR的有前景的影像方法。
- 作者认为SULpeak下降超过63.92%可能为选择新辅助治疗后可否免除手术的患者提供有价值指导。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neoadjuvant therapy in patients with locally advanced rectal cancer (LARC) has achieved good pathologic complete response (pCR) rates, potentially eliminating the need for surgical intervention. This study investigated preoperative methods for predicting pCR after neoadjuvant short-course radiotherapy (SCRT) combined with immunochemotherapy. Methods: Treatment-naïve patients with histologically confirmed LARC were enrolled from February 2023 to July 2023. Before surgery, the patients received neoadjuvant SCRT followed by 2 cycles of capecitabine and oxaliplatin plus camrelizumab. 68Ga-labeled fibroblast activation protein inhibitor ([68Ga]Ga-FAPI-04) PET/MRI, [18F]FDG PET/CT, and contrast-enhanced MRI were performed before treatment initiation and before surgery in each patient. PET and MRI features and the size and number of lesions were also collected from each scan. Each parameter's sensitivity, specificity, and diagnostic cutoff were derived via receiver-operating-characteristic curve analysis. Results: Twenty eligible patients (13 men, 7 women; mean age, 60.2 y) were enrolled and completed the entire trial, and all patients had proficient mismatch repair or microsatellite-stable LARC. A postoperative pCR was achieved in 9 patients (45.0%). In the visual evaluation, both [68Ga]Ga-FAPI-04 PET/MRI and [18F]FDG PET/CT were limited to forecasting pCR. Contrast-enhanced MRI had a low sensitivity of 55.56% to predict pCR. In the quantitative evaluation, [68Ga]Ga-FAPI-04 change in SULpeak percentage, where SULpeak is SUVpeak standardized by lean body mass, had the largest area under the curve (0.929) with high specificity (sensitivity, 77.78%; specificity, 100.0%; cutoff, 63.92%). Conclusion: [68Ga]Ga-FAPI-04 PET/MRI is a promising imaging modality for predicting pCR after SCRT combined with immunochemotherapy. The SULpeak decrease exceeding 63.92% may provide valuable guidance in selecting patients who can forgo surgery after neoadjuvant therapy.
引用
- Zhang X, Lin Z, Feng Y, et al. Predicting Pathologic Complete Response in Locally Advanced Rectal Cancer with [68Ga]Ga-FAPI-04 PET, [18F]FDG PET, and Contrast-Enhanced MRI: Lesion-to-Lesion Comparison with Pathology. J Nucl Med. 2024. PMID: 39353648. doi:10.2967/jnumed.124.267581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。